{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:02:11Z","timestamp":1774364531307,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ophtha.2023.08.008","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:05:59Z","timestamp":1697699159000},"page":"1114-1117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infections from Over-the-Counter Artificial Tears: Implications for Patients and Clinicians"],"prefix":"10.1016","volume":"130","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ophtha.2023.08.008_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1542-0124(12)70131-3","article-title":"Compliance issues in manufacturing of drugs","volume":"1","author":"Kaufman","year":"2003","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2023.08.008_bib3","author":"Howard"},{"issue":"2","key":"10.1016\/j.ophtha.2023.08.008_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jtos.2017.01.008","article-title":"Pipeline: Chemistry matters","volume":"15","author":"Novack","year":"2017","journal-title":"Ocul Surf"},{"issue":"6","key":"10.1016\/j.ophtha.2023.08.008_bib8","first-page":"39","article-title":"The Akorn bankruptcy","volume":"27","author":"Williams","year":"2023","journal-title":"Eyenet"},{"issue":"12","key":"10.1016\/j.ophtha.2023.08.008_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","article-title":"Compounding of low-concentration atropine for myopia control","volume":"48","author":"Richdale","year":"2022","journal-title":"Eye Contact Lens"},{"issue":"6","key":"10.1016\/j.ophtha.2023.08.008_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","article-title":"Compounded 0.01% atropine\u2014what\u2019s in the bottle?","volume":"49","author":"Richdale","year":"2023","journal-title":"Eye Contact Lens"},{"issue":"9","key":"10.1016\/j.ophtha.2023.08.008_bib15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1089\/jop.2020.0034","article-title":"Peri-operative intracameral antibiotics: the perfect storm?","volume":"36","author":"Novack","year":"2020","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2023.08.008_bib16","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.ajo.2020.09.014","article-title":"Off-label use as a standard of care","volume":"224","author":"Novack","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2023.08.008_bib17","first-page":"154","article-title":"Adjunctive antifibrotic therapy with mitomycin C and 5-fluorouracil: a review of their use in glaucoma surgery and considerations around ophthalmic compounding","volume":"2","author":"Fiscella","year":"2019","journal-title":"Curr Trends Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2023.08.008_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","article-title":"An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab","volume":"153","author":"Goldberg","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2023.08.008_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3201\/eid2101.141040","article-title":"Endophthalmitis outbreak associated with repackaged bevacizumab","volume":"21","author":"Edison","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.ophtha.2023.08.008_bib21","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/IAE.0000000000002351","article-title":"Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab","volume":"39","author":"Bavinger","year":"2019","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.ophtha.2023.08.008_bib22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a\u00a0nationwide study in France","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2023.08.008_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaophthalmol.2018.7089","article-title":"The argument for sterile loading of all intravitreal injections and the benefit of replicated results","volume":"137","author":"VanderBeek","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ophtha.2023.08.008_bib24","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","article-title":"The association between intravitreal steroids and post-injection endophthalmitis rates","volume":"122","author":"VanderBeek","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ophtha.2023.08.008_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ICO.0b013e3182910036","article-title":"Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases","volume":"32","author":"Thanathanee","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2023.08.008_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2017.03.030","article-title":"The growing \u201cstem cell clinic\u201d problem","volume":"177","author":"Kuriyan","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2023.08.008_bib27","series-title":"Cell-Based Therapy for Degenerative Retinal Disease","article-title":"Regulatory requirements for cell-based therapy for degenerative retinal disease","author":"Novack","year":"2019"},{"key":"10.1016\/j.ophtha.2023.08.008_bib28","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ophtha.2023.06.003","article-title":"Association of artificial tears with ocular and systemic infection: carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA) outbreak","volume":"130","author":"Velcani","year":"2023","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2023.08.008_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaophthalmol.2023.1549","article-title":"Association of serious adverse effects with the contamination of ocular medications\u2014a global perspective","volume":"141","author":"Prajna","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2023.08.008_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaophthalmol.2023.1109","article-title":"Multidrug-resistant Pseudomonas aeruginosa keratitis associated with artificial tear use","volume":"141","author":"Shoji","year":"2023","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023005729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642023005729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:22:58Z","timestamp":1716294178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642023005729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0161642023005729"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.008","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections from Over-the-Counter Artificial Tears: Implications for Patients and Clinicians","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2023.06.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}